In a phase II clinical study (NCT00721409), the inclusion of palbociclib (125 mg/day) to letrozole (2.5 mg/day) showed significant improvement in progression-free survival with progressive ER + and HER2 − breast cancer [74]. Here, ERBB2 is linked to breast carcinoma.